Hemolytic anemia is not a frequent complication of ABO unmatched renal allografts from living related donors.

In summary, we could not document an increased incidence of HA nor a detrimental effect of CyA use in our recipients of ABO-unmatched LRD kidneys. Thus, it would appear that the incidence of HA in this situation is low enough that no special pretreatment of the kidney transplant or recipient is warranted. Since the long-term survival of ABO-unmatched LRD kidneys was equivalent to that of ABO-matched recipients there is no reason to select against them, or avoid the use of CyA. Rather a severe pretransplant anemia may predispose to a delayed recovery from anemia after transplantation.